Lakefront Biotherapeutics - Sponsored ADR LKFT
29.38
(0.98)
(3.23%)
as of 25 Sep
- Market cap
- $2.0B
- P/E
- 0.0×
Follow LKFT
Growth Flags
show if company had growth for consecutive years
| Older periods | Jun '25 | Sep '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
0.00% | 0.00% | (0.55%) | 0.00% | |
| 0.00% | 0.00% | (0.45%) | 0.00% | ||
ROIC |
0.00% | 0.00% | (49.18%) | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | (0.54%) | 0.00% | |
Average Days of Receivables |
0.00 | 0.00 | 81.84 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | (8.09) | 0.00 | |
Free Cash Flow |
(689.94) | (808.33) | (532.79) | (524.53) | |
Capital Expenditures |
(165.54) | (108.93) | (23.16) | (16.58) | |
Piotroski F-Score |
— | — | 3.00 | — | |
| Other line items | |||||
Cash ROIC |
(8.02%) | (10.88%) | (6.98%) | (7.93%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 3.54 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.24 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.62 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 1,415.08 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 261.44 | 0.00 | |
Tax Rate |
— | — | (0.03) | — | |
Research and Development Expense of Revenue |
— | — | 146.51% | — | |
Selling, General and Administrative Expense of Revenue |
— | — | 65.79% | — | |
Share Based Compensation of Revenue |
— | — | 0.00% | — | |
Interest Coverage |
— | — | 0.00 | — | |
Operating CF/Net income |
0.00 | 0.00 | 26.52 | 0.00 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
— | — | 4.28 | — | |
Operating CF per Share |
0.00 | 0.00 | (7.74) | 0.00 | |
Capex per Share |
0.00 | 0.00 | (0.35) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.08 | 0.00 | |
Net Profit Margin |
— | — | (6.81%) | — |
Columns are period end dates